Paul Brennan

CBO at Eupraxia

Speaker

Paul Brennan is the Chief Business Officer at Eupraxia Pharmaceuticals, a Phase 2 company developing a novel product for Eosinopjilic Esophagitis. Paul has more than 35 years’ experience in the pharma and biotech industries working in Canada, US, Sweden and the UK. Paul has worked in both Big Pharma (AstraZeneca) and Biotech (including AnorMED, Aspreva, Tekmira, Aquinox and NervGen) in regulatory affairs, business development and in general management. He has participated in the development and/or commercialization of more than 15 products that have advanced from clinical development through to approval and has a deal sheet of business development and/or financing transactions totally over $3 billion.